The E3 ubiquitin ligase RNF135 modulates chemotherapy resistance to oxaliplatin for colorectal cancer by modulating autophagy

Tissue Cell. 2024 Feb:86:102282. doi: 10.1016/j.tice.2023.102282. Epub 2023 Nov 30.

Abstract

Background: RING finger protein 135 plays an important role in tumorigenesis and is associated with drug resistance.

Methods: Bioinformatics analysis showed that RNF135 was significantly differentially expressed in colorectal cancer. RT-qPCR and western blot were used to detect the expression of RNF135. Immunohistochemical analysis were used to measure the expression of RNF135 and Ki-67.

Results: The expression of RNF135 was up-regulated in human tissue samples and colorectal cancer and was positively correlated with Ki-67. Compared with oxaliplatin sensitive patients, RNF135 expression levels were higher in the tissue of resistant patients. The regulatory effect of RNF135 on colorectal cancer cells was further investigated in vitro. Therefore, inhibition of autophagy by down-regulating RNF135 can partially increase its susceptibility to oxaliplatin.

Keywords: Autophagy; Chemotherapy resistance; Colorectal cancer; RNF135.

MeSH terms

  • Autophagy / genetics
  • Cell Line, Tumor
  • Colorectal Neoplasms* / drug therapy
  • Colorectal Neoplasms* / genetics
  • Colorectal Neoplasms* / metabolism
  • Humans
  • Ki-67 Antigen
  • Oxaliplatin / pharmacology
  • Oxaliplatin / therapeutic use
  • Ubiquitin-Protein Ligases* / genetics
  • Ubiquitin-Protein Ligases* / metabolism

Substances

  • Oxaliplatin
  • Ubiquitin-Protein Ligases
  • Ki-67 Antigen
  • RNF135 protein, human